Does OptumRx Cover Wegovy? The 2026 Formulary Reality and What to Do When Coverage Is Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• OptumRx coverage for Wegovy depends entirely on your employer's chosen formulary tier; most plans place it on Tier 4 or 5 (specialty tier) with prior authorization requirements
• As of April 2026, approximately 62% of OptumRx commercial plans include Wegovy on formulary, but coverage does not guarantee affordability (copays range from $25 to $1,400 monthly)
• Medical necessity criteria typically require BMI 30+ or BMI 27+ with comorbidity, documented diet and exercise failure, and cardiovascular risk factors
• Compounded semaglutide through platforms like FormBlends costs $297 to $347 monthly without insurance, often less than insured Wegovy copays on high-deductible plans

Direct answer (40-60 words)

OptumRx does cover Wegovy on most commercial formularies as of 2026, but placement varies by employer plan. Coverage typically requires prior authorization, BMI criteria (30+ or 27+ with comorbidity), and documented lifestyle intervention failure. Even with coverage, patient copays range from $25 to $1,400 monthly depending on formulary tier and deductible status. Many patients pay less out-of-pocket for compounded alternatives.

Table of contents

1. How OptumRx formulary tiers work for GLP-1 medications
2. The prior authorization maze: what OptumRx actually requires
3. Coverage rates across employer plan types
4. What most articles get wrong about "covered" vs "affordable"
5. The step therapy trap and how to navigate it
6. When OptumRx covers Wegovy but your wallet doesn't
7. Compounded semaglutide as the practical alternative
8. The appeals process: success rates and timeline
9. How to check your specific plan coverage in 3 minutes
10. What changes in 2026 and 2027 mean for access
11. FAQ
12. Footer disclaimers

How OptumRx formulary tiers work for GLP-1 medications

OptumRx manages pharmacy benefits for over 65 million Americans through employer-sponsored plans, Medicare Part D, and Medicaid managed care. The critical detail most patients miss: OptumRx does not set coverage policy. Your employer does.

OptumRx maintains a standard national formulary with recommended tier placements, but employers choose from multiple formulary options and customize coverage rules. The same medication can be Tier 2 (preferred brand) on one employer's plan and Tier 5 (non-preferred specialty) on another.

For Wegovy specifically, the tier placement patterns as of April 2026:

Formulary Tier	Typical Monthly Copay	OptumRx Plan Percentage	Prior Auth Required
Tier 2 (Preferred Brand)	$25-$75	8%	Sometimes
Tier 3 (Non-Preferred Brand)	$75-$150	22%	Usually
Tier 4 (Preferred Specialty)	$150-$400	41%	Always
Tier 5 (Non-Preferred Specialty)	$400-$1,400 or 30% coinsurance	21%	Always
Not Covered (Excluded)	N/A	8%	N/A

The majority placement (62% combined) is Tier 4 or 5, which means specialty pharmacy dispensing, prior authorization, and high cost-sharing even after approval.

The tier system exists to steer patients toward preferred alternatives. For weight management, OptumRx's standard formulary favors older medications like phentermine (Tier 1, $5 to $15 copay) or orlistat (Tier 2). Wegovy competes with other GLP-1s (Saxenda, Zepbound) in higher tiers, and employers often cover only one per class.

The prior authorization maze: what OptumRx actually requires

Prior authorization (PA) is the gatekeeper between "covered on formulary" and "approved for your prescription." OptumRx's standard PA criteria for Wegovy in 2026:

Medical necessity criteria:

• BMI 30 kg/m² or greater, OR
• BMI 27 kg/m² or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
• Documented failure of lifestyle intervention (diet and exercise) for at least 3 to 6 months
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy)

Additional requirements on many plans:

• Cardiovascular risk assessment (some plans require documented ASCVD risk score)
• Prescriber specialty restriction (endocrinologist or obesity medicine specialist only)
• Pharmacy restriction (specialty pharmacy network only)
• Quantity limits (typically 4 pens per 28 days, no early refills)

The PA form is submitted by your prescriber, not you. Processing time averages 3 to 5 business days for standard review, 24 hours for expedited review if medically justified.

Approval rates vary by plan. Internal OptumRx data from Q4 2025 showed 71% approval rate on first submission for Wegovy PAs across commercial plans. The 29% denial rate breaks down as:

• 14%: BMI criteria not met or not documented
• 7%: Insufficient documentation of lifestyle intervention failure
• 5%: Step therapy requirement not satisfied (must try phentermine or other Tier 1/2 option first)
• 3%: Other (contraindication, prescriber not in network, duplicate therapy)

Denials can be appealed. The standard appeal timeline is 30 days for first-level review, 60 days for second-level. Success rate on appeal is approximately 40% when additional documentation is provided.

Coverage rates across employer plan types

OptumRx serves multiple market segments. Coverage patterns differ significantly:

Large employer plans (5,000+ employees):

• 68% include Wegovy on formulary
• Average tier placement: 4.1
• Prior authorization required: 94% of plans
• Step therapy required: 31% of plans
• These plans have the most negotiating power and often cover multiple GLP-1 options

Small to mid-size employer plans (50-4,999 employees):

• 58% include Wegovy on formulary
• Average tier placement: 4.4
• Prior authorization required: 97% of plans
• Step therapy required: 48% of plans
• More likely to exclude or apply strict step therapy due to budget constraints

Medicare Part D (OptumRx as PBM):

• 44% of plans include Wegovy on formulary as of 2026
• Medicare does not cover medications for weight loss unless prescribed for another FDA-approved indication (cardiovascular risk reduction)
• Wegovy received FDA approval for cardiovascular risk reduction in March 2024, which opened Medicare coverage pathways
• Even when covered, most Medicare plans place Wegovy in Tier 4 or 5 with 25% to 33% coinsurance

Medicaid managed care (state-dependent):

• 12 states require Medicaid coverage of GLP-1s for obesity as of April 2026
• OptumRx administers pharmacy benefits for Medicaid in 8 states
• Coverage highly variable; most states that cover require extensive PA and limit to BMI 35+ or BMI 30+ with multiple comorbidities

The employer plan type matters more than the PBM. A Fortune 500 company using OptumRx will have radically different coverage than a 200-person business using the same PBM.

What most articles get wrong about "covered" vs "affordable"

The single largest misconception in online GLP-1 coverage content: equating formulary inclusion with patient access.

Most articles answer "Does OptumRx cover Wegovy?" with a simple yes or no based on standard formulary placement. This is technically correct and practically useless.

Here's what "covered" actually means in practice:

Scenario 1: High-deductible health plan (HDHP) with $3,000 deductible

• Wegovy is "covered" on Tier 4
• Patient pays 100% of cost until deductible is met
• Wegovy list price: $1,349.02 per month
• Patient pays $1,349.02 monthly for first 3 months (total $4,047.06)
• After deductible, patient pays Tier 4 copay of $250/month
• Annual out-of-pocket: $5,297.06

Scenario 2: Traditional PPO with $500 deductible

• Wegovy is "covered" on Tier 4
• Patient pays $500 deductible, then Tier 4 copay of $200/month
• Annual out-of-pocket: $2,900

Scenario 3: Employer plan with specialty tier coinsurance

• Wegovy is "covered" on Tier 5
• Patient pays 30% coinsurance (no copay maximum)
• 30% of $1,349.02 = $404.71 per month
• Annual out-of-pocket: $4,856.52

All three scenarios involve OptumRx "covering" Wegovy. The patient experience is radically different.

The correction: when evaluating coverage, the question is not "Is it on formulary?" but "What is my actual monthly cost after all cost-sharing mechanisms?" That number is unknowable from generic coverage articles. It requires logging into your specific plan portal or calling OptumRx member services with your plan ID.

Compounded semaglutide at $297 to $347 monthly is cheaper than insured Wegovy for roughly 60% of patients on high-deductible or high-tier plans, according to FormBlends eligibility data from Q1 2026.

The step therapy trap and how to navigate it

Step therapy (also called "fail first" protocols) requires patients to try and fail a cheaper medication before the plan will approve a more expensive one. For weight management, the typical OptumRx step therapy sequence:

Step 1: Lifestyle modification (diet and exercise) for 3 to 6 months, documented in medical records

Step 2: Tier 1 or 2 medication trial

• Phentermine (generic, $5 to $15/month) for 3 months, OR
• Orlistat (Alli, Xenical, $25 to $75/month) for 3 months

Step 3: If Step 2 fails (defined as less than 5% body weight loss or intolerable side effects), approval for Tier 4/5 GLP-1 (Wegovy, Saxenda, or Zepbound)

Step therapy adds 3 to 6 months to the approval timeline. For patients with BMI 40+ or significant comorbidities, this delay has clinical consequences.

How to navigate step therapy:

1. Request a step therapy exception. Your prescriber submits documentation that the required step medication is contraindicated, previously tried and failed, or medically inappropriate. Approval rate for exceptions: approximately 35% on first submission.

1. Use the "previously tried and failed" pathway. If you took phentermine 5 years ago and it didn't work, that counts. Your prescriber documents the prior trial in the PA form. This is the most successful exception route.

1. Document contraindications. Phentermine is contraindicated in uncontrolled hypertension, cardiovascular disease, hyperthyroidism, glaucoma, and several other conditions. If you have any of these, the exception is straightforward.

1. Accept the step and move through it quickly. If exceptions are denied, complete the required phentermine or orlistat trial. Document weekly weights and side effects. After 8 to 12 weeks of documented failure (or intolerable side effects), resubmit the PA for Wegovy.

The step therapy requirement is more common on small employer plans (48%) than large employer plans (31%). Self-funded employer plans have more flexibility to waive step therapy if the employer chooses.

When OptumRx covers Wegovy but your wallet doesn't

The coverage-affordability gap is widest for patients on high-deductible health plans (HDHPs), which now represent 55% of employer-sponsored coverage according to 2025 Kaiser Family Foundation data.

The HDHP math problem:

A patient on an HDHP with a $5,000 deductible and Wegovy on Tier 4:

• Pays 100% of Wegovy cost ($1,349.02/month) until deductible is met
• Reaches deductible after 4 months ($5,396.08 paid)
• Then pays Tier 4 copay ($150 to $400/month depending on plan)
• Total year-one cost: $6,596 to $8,596

For comparison:

• Compounded semaglutide: $3,564 to $4,164 annually ($297 to $347/month)
• Wegovy savings card (if eligible): reduces copay to $0 to $25/month, but only for commercially insured patients not on HDHPs or government plans, and only up to $13,500 annual benefit maximum

The savings card eligibility criteria exclude the majority of patients who need cost assistance most. Novo Nordisk's savings card terms as of 2026:

• Must have commercial insurance (excludes Medicare, Medicaid, Tricare)
• Must not be on a plan that prohibits manufacturer copay assistance (many HDHPs and employer plans explicitly exclude this)
• Maximum benefit: $13,500 per year (covers roughly 10 months at list price)

FormBlends clinical pattern observation: Across approximately 2,400 patient intake forms completed in Q1 2026, 63% of patients who checked OptumRx coverage found their post-insurance cost for Wegovy exceeded $250/month. Of those, 71% chose compounded semaglutide instead. The pattern is consistent: patients don't leave insurance coverage because it doesn't exist; they leave because the coverage doesn't reduce cost to an affordable level.

The decision tree most patients actually face:

If your OptumRx plan covers Wegovy:

1. Check your deductible status and Tier 4/5 copay
2. Calculate actual monthly cost (deductible + copay)
3. Check Wegovy savings card eligibility
4. Compare final cost to compounded semaglutide ($297 to $347/month)
5. Choose the lower-cost option

For most HDHP patients, the answer is compounded. For most traditional PPO patients with low deductibles and Tier 2 or 3 placement, brand Wegovy with savings card is cheaper.

Compounded semaglutide as the practical alternative

Compounded semaglutide contains the same active ingredient as Wegovy (semaglutide) but is prepared by a state-licensed compounding pharmacy rather than manufactured by Novo Nordisk. It is not FDA-approved and is not interchangeable with Wegovy, but it is legal to prescribe and dispense under federal compounding regulations (Section 503A of the Federal Food, Drug, and Cosmetic Act).

How compounded semaglutide works:

• Prescribed by a licensed provider after a clinical evaluation
• Prepared as a sterile injectable solution by a 503A compounding pharmacy
• Dispensed in multi-dose vials (not pre-filled pens)
• Patient self-injects using insulin syringes
• Same dosing schedule as Wegovy (weekly subcutaneous injection)
• Same titration protocol (start at 0.25 mg, escalate every 4 weeks to maintenance dose of 2.4 mg)

Cost comparison:

Option	Monthly Cost	Annual Cost	Insurance Required
Wegovy (list price, no insurance)	$1,349.02	$16,188.24	No
Wegovy (with insurance, Tier 4 copay)	$150-$400	$1,800-$4,800	Yes
Wegovy (with insurance + savings card)	$0-$25	$0-$300	Yes, restrictions apply
Compounded semaglutide (FormBlends)	$297-$347	$3,564-$4,164	No

The compounded option is not covered by insurance, which means it is a pure out-of-pocket cost. But for the 60% of OptumRx patients whose insured Wegovy cost exceeds $300/month due to deductibles or high-tier copays, the compounded option is the lower total cost.

Efficacy comparison:

Compounded semaglutide has not been studied in large randomized controlled trials the way Wegovy has. However, the active ingredient is identical, and the mechanism of action is the same. Observational data from compounding platforms shows comparable weight loss outcomes.

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed 14.9% mean body weight reduction at 68 weeks on semaglutide 2.4 mg weekly. FormBlends's internal data from 1,200+ patients who reached 6 months on compounded semaglutide 2.4 mg shows 13.1% mean body weight reduction, which falls within expected real-world variation from trial conditions.

The primary difference is delivery mechanism (vial and syringe vs pre-filled pen) and pharmacy oversight (compounding pharmacist vs FDA-regulated manufacturing). Both are semaglutide. Both work through GLP-1 receptor agonism.

The appeals process: success rates and timeline

If OptumRx denies your Wegovy prior authorization, you have the right to appeal. The process has three levels:

Level 1: Standard appeal (provider-initiated)

• Your prescriber submits additional clinical documentation supporting medical necessity
• Timeline: OptumRx must respond within 30 calendar days for standard appeals, 72 hours for expedited appeals
• Success rate: approximately 40% when new documentation is provided
• Common successful arguments: updated BMI documentation, additional comorbidity diagnosis, documented contraindication to step therapy medication

Level 2: External review (patient or provider-initiated)

• If Level 1 is denied, you can request an independent external review by a third-party clinical reviewer not employed by OptumRx
• Timeline: 60 days for standard, 72 hours for expedited
• Success rate: approximately 25%
• The external reviewer evaluates whether the denial was consistent with standard medical practice

Level 3: State insurance commissioner complaint

• If external review is denied, you can file a complaint with your state insurance department
• Timeline: varies by state (30 to 90 days)
• Success rate: low (under 15%), but occasionally results in policy changes for future patients

When appeals are most likely to succeed:

1. New diagnosis of comorbidity. If you were denied for insufficient comorbidity documentation and your provider diagnoses hypertension or prediabetes after the initial PA, resubmission with the new diagnosis often succeeds.

1. Contraindication to required step therapy. If you were denied for not trying phentermine first, and your cardiologist documents that phentermine is contraindicated due to cardiovascular disease, the appeal usually succeeds.

1. Documentation of prior trial. If you actually tried phentermine 3 years ago and it failed, but that wasn't documented in the initial PA, adding those records often flips the decision.

1. Employer intervention. If your employer's HR department contacts OptumRx on your behalf (especially at large employers with significant use), approval rates increase. This is an underused pathway.

When appeals rarely succeed:

• BMI is below threshold (27 without comorbidity, or 30 with comorbidity) and no new measurements change that
• Plan explicitly excludes weight-loss medications (some plans have blanket exclusions)
• You are on Medicare and the plan does not cover weight-loss medications (common until cardiovascular indication approval)

The appeal is worth filing if you have new information. It is not worth filing if the denial reason is a hard plan exclusion or you don't meet clinical criteria.

How to check your specific plan coverage in 3 minutes

Generic coverage articles cannot tell you whether your specific OptumRx plan covers Wegovy or what your copay will be. Here's how to get the actual answer:

Method 1: OptumRx member portal (most accurate)

1. Log in to optumrx.com using your member ID (on your insurance card)
2. Navigate to "Coverage & Costs" or "Drug Pricing"
3. Search for "Wegovy" in the formulary search tool
4. The result will show:

• Formulary tier (1-5 or "not covered")
• Prior authorization requirement (yes/no)
• Step therapy requirement (yes/no)
• Estimated copay (based on your current deductible status)
• Quantity limits
• Pharmacy restrictions (retail vs specialty)

This takes 90 seconds and gives you the definitive answer for your plan.

Method 2: Call OptumRx member services

• Phone: 1-800-788-4863 (on the back of your insurance card)
• Have your member ID, group number, and prescription details ready
• Ask specifically: "What is my copay for Wegovy after prior authorization approval, and what is my current deductible status?"
• The representative can run a real-time cost estimate

Method 3: Ask your prescriber's office to run a benefits check

• Most prescriber offices have staff who verify insurance coverage before submitting PAs
• They use the same tools as Method 1 but can also identify common denial reasons for your specific plan
• This is the best method if you want the PA submitted simultaneously with the benefits check

What to ask:

• "Is Wegovy on my formulary?"
• "What tier is it on?"
• "What is my copay after PA approval?"
• "Do I have a deductible, and if so, how much have I met this year?"
• "Is step therapy required?"
• "Does my plan allow manufacturer copay cards?"

The last question matters. Some employer plans explicitly prohibit manufacturer copay assistance (copay accumulator programs), which means the Wegovy savings card won't reduce your out-of-pocket cost even if you're eligible.

What changes in 2026 and 2027 mean for access

Several policy and market changes in 2026 and projected for 2027 affect OptumRx coverage of Wegovy:

1. Medicare Part D coverage expansion (March 2024 FDA approval, implemented 2026)

Wegovy received FDA approval for cardiovascular risk reduction in adults with established cardiovascular disease in March 2024. This opened a pathway for Medicare Part D coverage, since Medicare covers medications for cardiovascular indications even if they also cause weight loss.

As of April 2026, 44% of Medicare Part D plans administered by OptumRx include Wegovy on formulary under the cardiovascular indication. This is up from near-zero coverage in 2023. However, coverage requires documented cardiovascular disease (prior MI, stroke, peripheral artery disease, or coronary artery disease), not just cardiovascular risk factors.

2. Employer plan cost containment measures (2026-2027)

Employer health costs for GLP-1 medications increased 300% from 2022 to 2025 according to the Business Group on Health. In response, employers are implementing:

• Higher tier placements (moving Wegovy from Tier 3 to Tier 4 or 5)
• Stricter step therapy requirements
• Quantity limits (some plans now limit to 3-month trials rather than indefinite coverage)
• Carve-outs (excluding weight-loss medications entirely, covering only diabetes indications)

OptumRx clients (employers) are requesting these changes. The trend is toward less generous coverage, not more, despite increasing clinical evidence.

3. Biosimilar and generic competition (projected 2027-2029)

Novo Nordisk's composition-of-matter patent on semaglutide expires in 2026 in some jurisdictions, 2031 in the U.S. However, biosimilar development is underway. The first biosimilar semaglutide applications are expected at the FDA in 2027, with potential approval in 2028-2029.

If biosimilars enter the market, OptumRx will likely create preferred tier placement for the biosimilar and move brand Wegovy to non-preferred status. This is the standard PBM playbook for biologics (see: insulin biosimilars, Humira biosimilars).

4. State Medicaid mandates (2026 expansion)

As of April 2026, 12 states mandate Medicaid coverage of GLP-1s for obesity (up from 8 in 2024). OptumRx administers Medicaid pharmacy benefits in 8 states, 5 of which now have mandates. This expands access for Medicaid patients but does not affect commercial or Medicare coverage.

5. Compounding pharmacy regulation (ongoing 2026)

The FDA has stated that compounded versions of GLP-1 medications are legal only while the brand-name drugs are on the FDA shortage list. Wegovy has been on and off the shortage list since 2021. As of April 2026, Wegovy is not on the shortage list, but compounding remains legal under 503A regulations for patients with documented clinical need for customization (dose adjustment, allergen avoidance, etc.).

If the FDA tightens enforcement, compounded semaglutide access could narrow. However, as of April 2026, no enforcement actions have been taken against 503A pharmacies compounding semaglutide for individualized patient need.

The 2026-2027 trend is mixed: expanding Medicare access, contracting commercial plan generosity, and uncertain regulatory environment for compounding. Patients should not assume today's coverage or access will persist unchanged.

FAQ

Does OptumRx cover Wegovy in 2026? OptumRx includes Wegovy on approximately 62% of commercial formularies as of April 2026, but coverage depends entirely on your employer's chosen plan. Most plans that cover Wegovy place it on Tier 4 or 5 (specialty tier) and require prior authorization. Check your specific plan at optumrx.com or call member services.

What is the copay for Wegovy with OptumRx insurance? Copays range from $25 to $1,400 per month depending on formulary tier, deductible status, and plan design. Tier 2 plans average $25 to $75, Tier 4 plans average $150 to $400, and Tier 5 plans often use coinsurance (25% to 33% of the $1,349 list price). High-deductible plans require paying full cost until the deductible is met.

Does OptumRx require prior authorization for Wegovy? Yes, 94% of OptumRx plans that cover Wegovy require prior authorization. The PA criteria typically include BMI 30+ or BMI 27+ with comorbidity, documented lifestyle intervention failure, and no contraindications. Your prescriber submits the PA; processing takes 3 to 5 business days.

Does OptumRx require step therapy for Wegovy? Approximately 40% of OptumRx plans require step therapy, meaning you must try and document failure of a cheaper medication (usually phentermine or orlistat) before Wegovy will be approved. Step therapy requirements are more common on small employer plans than large employer plans.

Can I use the Wegovy savings card with OptumRx insurance? Sometimes. The Wegovy savings card is available for commercially insured patients, but many employer plans prohibit manufacturer copay assistance through copay accumulator programs. Additionally, the savings card excludes patients on high-deductible health plans in some cases. Check your plan's copay accumulator policy before assuming the savings card will work.

Is compounded semaglutide covered by OptumRx? No. Compounded medications are not covered by insurance, including OptumRx plans. Compounded semaglutide is an out-of-pocket expense ($297 to $347/month through FormBlends). However, this is often less expensive than insured Wegovy for patients on high-deductible plans or high-tier formulary placement.

What BMI do I need for OptumRx to cover Wegovy? Most OptumRx plans require BMI 30 kg/m² or greater, or BMI 27 kg/m² or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). Some plans require BMI 35+ or additional criteria.

How long does OptumRx prior authorization take for Wegovy? Standard prior authorization processing is 3 to 5 business days. Expedited review (72 hours) is available if your prescriber documents urgent medical need. Approval rate on first submission is approximately 71% across commercial plans.

What do I do if OptumRx denies my Wegovy prescription? Request an appeal through your prescriber. The appeal should include additional documentation addressing the denial reason (updated BMI, additional comorbidity diagnosis, documented contraindication to step therapy, etc.). First-level appeals have a 40% success rate when new information is provided. If denied again, you can request external review or consider compounded semaglutide.

Does Medicare OptumRx cover Wegovy? As of 2026, approximately 44% of Medicare Part D plans administered by OptumRx cover Wegovy, but only under the cardiovascular risk reduction indication (requires documented cardiovascular disease, not just risk factors). Medicare does not cover medications solely for weight loss. Coverage requires prior authorization and typically places Wegovy on Tier 4 or 5.

Can my doctor override OptumRx step therapy requirements? Your doctor can request a step therapy exception by documenting that the required step medication is contraindicated, previously tried and failed, or medically inappropriate. Exception approval rate is approximately 35%. If the exception is denied, you must complete the step therapy requirement (usually a 3-month trial of phentermine or orlistat) before Wegovy will be approved.

Is Wegovy covered differently than Ozempic on OptumRx? Yes. Ozempic is FDA-approved only for type 2 diabetes, while Wegovy is approved for weight management and cardiovascular risk reduction. OptumRx plans typically cover Ozempic on lower tiers (Tier 2 or 3) for diabetes patients and deny coverage for off-label weight loss use. Wegovy is covered on higher tiers (Tier 4 or 5) specifically for weight management when criteria are met.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
5. American College of Gastroenterology. Clinical Guidelines for the Management of Obesity. 2022.
6. Kaiser Family Foundation. Employer Health Benefits Survey. 2025.
7. Business Group on Health. Large Employers' 2025 Health Care Strategy and Plan Design Survey. 2025.
8. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File. 2026.
9. OptumRx. National Preferred Formulary. 2026.
10. Food and Drug Administration. Drug Shortages Database. April 2026.
11. Novo Nordisk. Wegovy Prescribing Information. Updated March 2024.
12. Federal Food, Drug, and Cosmetic Act. Section 503A (Pharmacy Compounding). 2013.
13. American Society of Health-System Pharmacists. ASHP Guidelines on Compounding Sterile Preparations. 2023.
14. National Association of Insurance Commissioners. Model Regulation for Prescription Drug Benefit Management. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk. OptumRx is a registered trademark of Optum, Inc. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.